Limits...
Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment.

Moustou AE, Alexandrou P, Stratigos AJ, Giannopoulou I, Vergou T, Katsambas A, Antoniou C - An Bras Dermatol (2014 Nov-Dec)

Bottom Line: VEGF-C expression on lymphatic vessels diminished after treatment with etanercept.Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation.The exact role of this alteration is not yet clear and more studies are necessary to confirm these results.

View Article: PubMed Central - PubMed

Affiliation: Medical School, University of Athens, Athens, Greece.

ABSTRACT

Background: Angiogenesis is an early stage of psoriatic lesion development, but less is known about lymphagiogenesis and its role in the development of psoriasis.

Objective: To examine the expression of specific lymphatic markers and lymphatic growth factors in untreated psoriatic skin, in the unaffected skin of patients and skin of healthy volunteers, as well as their alteration after treatment with an anti-TNF agent.

Methods: Immunohistochemistry for the lymphatic markers D2-40 and LYVE-1, in addition to the VEGF-C and VEGF-D growth factors, was performed in the skin biopsies of psoriatic lesions and adjacent non-psoriatic skin of 19 patients before and after treatment with etanercept, as well as in the skin biopsies of 10 healthy volunteers.

Results: The expressions of D2-40, VEGF-C and VEGF-D on lymphatic vessels underwent statistically significant increases in untreated psoriatic skin compared with non-lesional skin, in contrast to LYVE-1, which did not involve significant increase in expression in psoriatic skin. VEGF-C expression on lymphatic vessels diminished after treatment with etanercept. Moreover VEGF-C and VEGF-D staining on fibroblasts presented with higher expression in lesional skin than in non-lesional adjacent skin.

Conclusion: Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation. The exact role of this alteration is not yet clear and more studies are necessary to confirm these results.

Show MeSH

Related in: MedlinePlus

Granular staining of VEGF-C on LV wall (blue arrows). Intense VEGF-C staining infibroblasts was observed mostly on psoriatic skin (red arrows). A:psoriatic skin before treatment, B: psoriatic skin after treatment,C: normal skin of patient
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4230657&req=5

f03: Granular staining of VEGF-C on LV wall (blue arrows). Intense VEGF-C staining infibroblasts was observed mostly on psoriatic skin (red arrows). A:psoriatic skin before treatment, B: psoriatic skin after treatment,C: normal skin of patient

Mentions: The evaluation of LVs according to VEGF-C staining revealed a statistically increasednumber of LVs in psoriatic skin compared with non-psoriatic adjacent skin of patients(P=0.001). This difference remained after treatment with etanercept (P=0.011). We alsoobserved a decrease in LVs expressing VEGF-C in psoriatic skin after treatment(P=0.045). Comparing LV density in non-lesional skin of untreated patients with that ofhealthy volunteers' skin, we found significantly more LVs expressing VEGF-C innon-lesional skin of patients (P=0.004) - (Table2). VEGF-C staining in fibroblasts increased considerably in psoriatic skincompared with non-psoriatic skin before treatment (P<0.001) and after treatment(P<0.001) - (Figure 3). Interestingly, weobserved increased expression of VEGF-C in the fibroblast of normal adjacent skin ofpsoriatic patients before treatment, compared with normal skin after treatment(P=0.031). Moreover, VEGF-C expression was higher in fibroblasts for normal skin ofuntreated patients than in healthy individuals (P=0.047).


Expression of lymphatic markers and lymphatic growth factors in psoriasis before and after anti-TNF treatment.

Moustou AE, Alexandrou P, Stratigos AJ, Giannopoulou I, Vergou T, Katsambas A, Antoniou C - An Bras Dermatol (2014 Nov-Dec)

Granular staining of VEGF-C on LV wall (blue arrows). Intense VEGF-C staining infibroblasts was observed mostly on psoriatic skin (red arrows). A:psoriatic skin before treatment, B: psoriatic skin after treatment,C: normal skin of patient
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4230657&req=5

f03: Granular staining of VEGF-C on LV wall (blue arrows). Intense VEGF-C staining infibroblasts was observed mostly on psoriatic skin (red arrows). A:psoriatic skin before treatment, B: psoriatic skin after treatment,C: normal skin of patient
Mentions: The evaluation of LVs according to VEGF-C staining revealed a statistically increasednumber of LVs in psoriatic skin compared with non-psoriatic adjacent skin of patients(P=0.001). This difference remained after treatment with etanercept (P=0.011). We alsoobserved a decrease in LVs expressing VEGF-C in psoriatic skin after treatment(P=0.045). Comparing LV density in non-lesional skin of untreated patients with that ofhealthy volunteers' skin, we found significantly more LVs expressing VEGF-C innon-lesional skin of patients (P=0.004) - (Table2). VEGF-C staining in fibroblasts increased considerably in psoriatic skincompared with non-psoriatic skin before treatment (P<0.001) and after treatment(P<0.001) - (Figure 3). Interestingly, weobserved increased expression of VEGF-C in the fibroblast of normal adjacent skin ofpsoriatic patients before treatment, compared with normal skin after treatment(P=0.031). Moreover, VEGF-C expression was higher in fibroblasts for normal skin ofuntreated patients than in healthy individuals (P=0.047).

Bottom Line: VEGF-C expression on lymphatic vessels diminished after treatment with etanercept.Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation.The exact role of this alteration is not yet clear and more studies are necessary to confirm these results.

View Article: PubMed Central - PubMed

Affiliation: Medical School, University of Athens, Athens, Greece.

ABSTRACT

Background: Angiogenesis is an early stage of psoriatic lesion development, but less is known about lymphagiogenesis and its role in the development of psoriasis.

Objective: To examine the expression of specific lymphatic markers and lymphatic growth factors in untreated psoriatic skin, in the unaffected skin of patients and skin of healthy volunteers, as well as their alteration after treatment with an anti-TNF agent.

Methods: Immunohistochemistry for the lymphatic markers D2-40 and LYVE-1, in addition to the VEGF-C and VEGF-D growth factors, was performed in the skin biopsies of psoriatic lesions and adjacent non-psoriatic skin of 19 patients before and after treatment with etanercept, as well as in the skin biopsies of 10 healthy volunteers.

Results: The expressions of D2-40, VEGF-C and VEGF-D on lymphatic vessels underwent statistically significant increases in untreated psoriatic skin compared with non-lesional skin, in contrast to LYVE-1, which did not involve significant increase in expression in psoriatic skin. VEGF-C expression on lymphatic vessels diminished after treatment with etanercept. Moreover VEGF-C and VEGF-D staining on fibroblasts presented with higher expression in lesional skin than in non-lesional adjacent skin.

Conclusion: Remodeling of lymphatic vessels possibly occurs during psoriatic lesion development, parallel to blood vessel formation. The exact role of this alteration is not yet clear and more studies are necessary to confirm these results.

Show MeSH
Related in: MedlinePlus